GNLX Key Statistics, Chart & Performance
The current stock price of GNLX is 4.37 USD. In the past month the price decreased by -19.37%. In the past year, price increased by 87.55%.
GNLX Latest News, Press Relases and Analysis
GNLX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.61 | 394.34B | ||
| AMGN | AMGEN INC | 14.69 | 172.98B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.46 | 112.15B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.62 | 73.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 843.18 | 56.81B | ||
| INSM | INSMED INC | N/A | 41.92B | ||
| NTRA | NATERA INC | N/A | 33.00B | ||
| BIIB | BIOGEN INC | 10.78 | 26.47B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.17 | 20.65B | ||
| INCY | INCYTE CORP | 15.06 | 18.98B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.16B |
Related stock screener links
About GNLX
Company Profile
Genelux Corp. manufactures and markets drugs and virus strains solutions. The company is headquartered in Westlake Village, California and currently employs 24 full-time employees. The company went IPO on 2023-01-26. The firm is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Company Info
GENELUX CORP
2625 Townsgate Road, Suite 230
Westlake Village CALIFORNIA US
Employees: 24
Phone: 18052679889
GENELUX CORP / GNLX FAQ
What does GNLX do?
Genelux Corp. manufactures and markets drugs and virus strains solutions. The company is headquartered in Westlake Village, California and currently employs 24 full-time employees. The company went IPO on 2023-01-26. The firm is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
What is the current price of GNLX stock?
The current stock price of GNLX is 4.37 USD. The price decreased by -5.82% in the last trading session.
Does GNLX stock pay dividends?
GNLX does not pay a dividend.
What is the ChartMill technical and fundamental rating of GNLX stock?
GNLX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for GNLX stock?
GENELUX CORP (GNLX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.88).
Can you provide the market cap for GENELUX CORP?
GENELUX CORP (GNLX) has a market capitalization of 166.28M USD. This makes GNLX a Micro Cap stock.
GNLX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to GNLX. When comparing the yearly performance of all stocks, GNLX is one of the better performing stocks in the market, outperforming 93.08% of all stocks.
GNLX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GNLX. GNLX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GNLX Financial Highlights
Over the last trailing twelve months GNLX reported a non-GAAP Earnings per Share(EPS) of -0.88. The EPS increased by 7.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -127.56% | ||
| ROE | -171.45% | ||
| Debt/Equity | 0 |
GNLX Forecast & Estimates
12 analysts have analysed GNLX and the average price target is 19.72 USD. This implies a price increase of 351.26% is expected in the next year compared to the current price of 4.37.
For the next year, analysts expect an EPS growth of 9.47% and a revenue growth -100% for GNLX